Curie Therapeutics has appointed Bernard Lambert, PhD, as its new chief technology officer (CTO).
Lambert will lead the company's process development, manufacturing, and technical operations, the company said.
He brings more than 20 years of experience in radiopharmaceutical drug development, including leading commercial strategy and operations from investigational new drugs to new drug applications. Most recently he was president and chief operating officer of the U.S. subsidiary of Telix Pharmaceuticals.
Lambert has also served as vice president at Zevacor Pharma, Zevacor Molecular, and IBA Molecular, Curie Pharmaceutical said.
